9P GAIN PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX +/- ATEZOLIZUMAB. ARGO: A RANDOMISED PHASE II STUDY